Detalles de la búsqueda
1.
Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.
Bioorg Med Chem
; 23(10): 2387-407, 2015 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25882525
2.
Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
Bioorg Med Chem
; 22(17): 4998-5012, 2014 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25009002
3.
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.
Invest New Drugs
; 30(6): 2334-43, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22160853
4.
Miniaturizing bromodeoxyuridine incorporation enables the usage of flow cytometry for cell cycle analysis of adherent tissue culture cells for high throughput screening.
Cytometry A
; 77(10): 953-61, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-21290469
5.
The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Pharmacol Res
; 61(5): 437-48, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20026273
6.
Optimization of 6,6-dimethyl pyrrolo[3,4-c]pyrazoles: Identification of PHA-793887, a potent CDK inhibitor suitable for intravenous dosing.
Bioorg Med Chem
; 18(5): 1844-53, 2010 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20153204
7.
Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.
ACS Med Chem Lett
; 10(4): 534-538, 2019 Apr 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30996792
8.
Antitumor activity of edotecarin in breast carcinoma models.
Cancer Chemother Pharmacol
; 60(2): 229-35, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17089166
9.
Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model.
Clin Cancer Res
; 12(9): 2856-61, 2006 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16675581
10.
Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
Mol Cancer Ther
; 15(4): 628-39, 2016 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-26939704
11.
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.
J Med Chem
; 48(8): 2944-56, 2005 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-15828833
12.
Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
ChemMedChem
; 10(2): 276-95, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25430902
13.
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
J Med Chem
; 58(17): 6875-98, 2015 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-26222319
14.
Endothelial cells overexpressing basic fibroblast growth factor (FGF-2) induce vascular tumors in immunodeficient mice.
Angiogenesis
; 1(1): 102-116, 1997.
Artículo
en Inglés
| MEDLINE | ID: mdl-14517397
15.
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.
J Med Chem
; 47(13): 3367-80, 2004 Jun 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-15189033
16.
NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
Clin Cancer Res
; 19(13): 3520-32, 2013 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23674492
17.
Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125.
Biochem Pharmacol
; 84(5): 598-611, 2012 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22704958
18.
Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.
Exp Hematol
; 38(4): 259-269.e2, 2010 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-20167248
19.
Efficacy of PHA-848125, a cyclin-dependent kinase inhibitor, on the K-Ras(G12D)LA2 lung adenocarcinoma transgenic mouse model: evaluation by multimodality imaging.
Mol Cancer Ther
; 9(3): 673-81, 2010 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-20197397
20.
Transcriptional analysis of an E2F gene signature as a biomarker of activity of the cyclin-dependent kinase inhibitor PHA-793887 in tumor and skin biopsies from a phase I clinical study.
Mol Cancer Ther
; 9(5): 1265-73, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20423997